Q1 2026 earnings snapshot

TransMedics Group (TMDX) has just posted Q1 2026 results with revenue of US$173.9 million, basic EPS of US$0.21 and net income of US$7.3 million, set against a current share price of US$72.92. The company has reported revenue of US$121.6 million in Q4 2024 and US$173.9 million in Q1 2026, while quarterly basic EPS moved from US$0.20 to US$0.21 over the same span. With trailing earnings growth and a higher net profit margin in the background, this quarter’s numbers bring attention to how sustainably the margin profile holds up.

See our full analysis for TransMedics Group.

With the headline figures in place, the next step is to see how they compare with the widely held narratives about TransMedics, highlighting where market stories match the numbers and where they start to diverge.

Margins look stronger on a full year view

• On a trailing basis, TransMedics generated US$171.9 million of net income on US$635.9 million of revenue, which works out to a 27% net margin compared with 10% a year earlier in the data.
• What stands out for the bullish narrative is that this higher 27% margin is paired with very large year over year earnings growth of 251.2%. Consensus expectations in the balanced view call for earnings growth of about 11% per year and revenue growth of about 15.5% per year. This creates a gap between strong trailing profitability and the more measured growth path analysts are building into their models.
  • Supporters of the bullish view focus on the long term earnings growth rate of 73.7% per year over five years and the idea that expansion into additional organs and services could keep margins healthy. By contrast, the consensus narrative in the data assumes profit margins rise from 13.5% to 17.5% over the next three years, which is below the trailing 27% figure.
  • For you as an investor, the key tension is that the business has recently operated at a higher margin level than the consensus narrative assumes for the future. It is therefore worth asking whether those current economics are temporary or closer to a new baseline.

TransMedics' recent profitability and growth figures give bulls plenty to talk about, but the gap to more cautious forecasts is exactly where the long term debate starts to get interesting. 🐂 TransMedics Group Bull Case

Valuation signals show a wide gap to DCF fair value

• Using the supplied metrics, the stock trades on a trailing P/E of 14.7x versus peer and industry averages of 41.2x and 23.9x respectively. A DCF fair value of US$198.53 sits well above the current share price of US$72.92 and above the allowed analyst price target reference of US$117.89.
• Bears point out in their narrative that even the more cautious analyst cohort is still using future P/E multiples above the current US medical equipment industry average. Yet the present data shows TransMedics on a materially lower trailing P/E, which challenges the idea that the stock is already priced for aggressive expectations.
  • The bearish narrative works off scenarios where 2029 earnings reach around US$188.9 million and the stock trades at 28.2x those earnings. Today, however, the combination of US$171.9 million of trailing net income and a 14.7x P/E suggests the market price is not matching that kind of multiple in the current figures.
  • For a reader comparing these views, the numbers show that bearish concerns about valuation rest on forward assumptions, while the trailing data in this snapshot presents a lower multiple and a DCF fair value almost 3x the current share price.

Skeptics focus on what could go wrong with growth and margins, but the current P/E discount and DCF fair value gap keep the valuation side of the story very much alive. 🐻 TransMedics Group Bear Case

Quarterly EPS looks modest beside very large trailing gains

• Q1 2026 basic EPS of US$0.21 compares with trailing twelve month EPS of US$5.03, and the trailing figure in the data has grown by a very large 251.2% over the past year. This makes the single quarter look relatively small in the context of the last four quarters combined.
• Consensus narrative commentary leans on the idea that revenue can grow about 18.8% annually and earnings can rise from US$71.7 million to US$155.9 million by 2028. When you line that up against the recent US$171.9 million of trailing net income and US$5.03 of trailing EPS, it suggests analysts are effectively smoothing out the past surge rather than extrapolating it straight into their forward numbers.
  • That contrast can be useful for you because it shows how the balanced view treats the recent growth spurt as something that may not repeat at the same rate, even though the trailing data is strong.
  • If you are comparing the short term Q1 EPS of US$0.21 with those longer term forecasts, it is worth thinking about how much weight to place on any single quarter versus the full trailing year and the multi year scenarios analysts are using.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for TransMedics Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both optimism and concern running through this story, now is the time to look at the numbers yourself and decide what really matters here, starting with the 4 key rewards and 1 important warning sign.

See What Else Is Out There

TransMedics' story includes strong trailing figures, but the reliance on forward assumptions and questions around how durable current margins are leaves uncertainty around consistency.

If you want ideas where pricing already looks more conservative, take a few minutes to compare this situation with companies screened as 44 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.